deferasirox has been researched along with HbS Disease in 37 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (21.62) | 29.6817 |
| 2010's | 24 (64.86) | 24.3611 |
| 2020's | 5 (13.51) | 2.80 |
| Authors | Studies |
|---|---|
| Delicou, S; Koskinas, J; Manganas, K; Xydaki, A | 1 |
| Qadah, T | 1 |
| Guerriero, R; Guilliams, KP; Hulbert, ML; Shinawi, MS; Stoll, JM; Towerman, AS; Willis, DN | 1 |
| Benites, BD; Costa, FF; Gilli, SCO; Olalla Saad, ST; Ribeiro, LB; Soares, EA | 1 |
| Bejaoui, M; Bonifazi, D; Ceci, A; Christou, S; Cosmi, C; Cuccia, L; Del Vecchio, GC; Della Pasqua, O; El-Beshlawy, A; Felisi, M; Filosa, A; Hassab, H; Kattamis, A; Kreka, M; Maggio, A; Origa, R; Putti, MC; Reggiardo, G; Sherief, L; Spino, M; Telfer, P; Tempesta, B; Tricta, F; Tsang, YC; Vitrano, A; Zaka, A | 1 |
| Crawford, RD; Oyedeji, CI; Shah, N | 1 |
| Sivaramakrishnan, G; Sridharan, K | 1 |
| Doree, C; Estcourt, LJ; Fisher, SA; Fortin, PM; Hopewell, S; Madgwick, KV; Trivella, M | 1 |
| Hassan, MK; Mohsin, AM | 1 |
| Akın, M; Akkaynak, D; Antmen, B; Apak, H; Aral, YZ; Aydogan, G; Ayhan, AC; Biner, B; Çalışkan, Ü; Eren, TG; Ertem, M; Gümrük, F; İrken, G; Işık Balcı, Y; Karakaş, Z; Karasu, G; Kazancı, EG; Koç, A; Koçak, Ü; Küpesiz, OA; Kurtoğlu, E; Meral Güneş, A; Oktay, G; Oymak, Y; Patıroğlu, T; Salcioglu, Z; Şaşmaz, İ; Söker, M; Timur, Ç; Tunç, B; Türkkan, E; Ünal, S; Uygun, V; Vergin, C; Yeşilipek, MA; Yıldırmak, Y | 1 |
| Alvarez, O; Aygun, B; Bonner, M; Flanagan, J; Lockhart, A; Miller, ST; Mueller, BU; Owen, W; Schultz, W; Scott, JP; Ware, RE; Yovetich, NA | 1 |
| Walia, HS; Yan, J | 1 |
| Barrette, S; Files, B; Habr, D; Minniti, CP; Torres, M; Vichinsky, E; Zhang, Y | 1 |
| Gadong, N; Hemmaway, C; Kaya, B; Newell, H; Simmons, A; Telfer, P; Tsouana, E; Whitmarsh, S | 1 |
| Cohen, AR; Davis, BR; Heeney, MM; Kwiatkowski, JL; Lee, MT; Odame, I; Owen, WC; Pressel, S; Rogers, ZR; Schultz, WH; St Pierre, T; Ware, RE; Wood, JC | 1 |
| Halligan, K; Hickling, M; Menaker, N; Nepo, A; Paige, J; Shur, N; Weintraub, L | 1 |
| Brewster, UC; McPhedran, P; Yusuf, B | 1 |
| Alvarez, O; Lewis, N; Lopez-Mitnik, G; Paley, C; Pow Sang, CD; Robinson, N; Rodriguez-Cortes, H | 1 |
| Cappellini, MD; Taher, A | 1 |
| Christoulas, D; Dimopoulou, M; Douskou, M; Mpoutou, E; Plata, E; Sioni, A; Terpos, E; Voskaridou, E | 1 |
| Antes, G; Bassler, D; Fleeman, N; Meerpohl, JJ; Niemeyer, C; Rücker, G | 1 |
| Inati, A; Khoriaty, E; Musallam, KM; Taher, AT | 1 |
| Brittenham, GM | 1 |
| Bernaudin, F; Coates, T; Deng, W; Forni, GL; Gardner, R; Giannone, V; Griffel, L; Hassell, K; Heeney, MM; Inusa, B; Kutlar, A; Lane, P; Mathias, L; Porter, J; Tebbi, C; Vichinsky, E; Wilson, F | 1 |
| Corral, M; Duh, MS; Guo, A; Jordan, LB; Sengupta, A; Vekeman, F | 1 |
| Belini Junior, E; Bonini-Domingos, CR; Cancado, RD; Chiattone, C; da Silva, DG; de Almeida, EA; Torres, Lde S | 1 |
| El-Beshlawy, A; Evangeli, M; Porter, JB | 1 |
| Alvarez, O; Cohen, AR; Garro, J; Kwiatkowski, JL; Lane, P; Mortier, N; Mueller, B; Nagasubramanian, R; Sarnaik, S; Schultz, W; Thompson, A; Ware, RE; Woods, GM; Yovetich, N | 1 |
| Bruniera, P; Cancado, R; Chiattone, C; de Moraes Bastos, R; Olivato, MC; Rezende Melo, M; Szarf, G | 1 |
| Armstrong, EP; Ballas, SK; Sasane, M; Skrepnek, GH; Snodgrass, SM | 1 |
| Ruivard, M | 1 |
| Bekiari, E; Mainou, M; Tsapas, A; Vetsiou, E; Vlachaki, E | 1 |
| Okpala, I | 1 |
| Alberti, D; Bernaudin, F; Coates, T; Eckman, J; Files, B; Fischer, R; Forni, GL; Fung, E; Hassell, K; Holland, J; Kelly, P; Lane, P; Marks, P; Mueller, BU; Okpala, I; Onyekwere, O; Porter, J; Ressayre-Djaffer, C; Swerdlow, P; Vichinsky, E; Wilson, F | 1 |
| Barton, JC | 1 |
| Hampton, T | 1 |
| Abetz, L; Baladi, JF; Coates, T; Coïc, L; Files, B; Fischer, R; Forni, GL; Lane, P; Marks, P; Mueller, BU; Onyekwere, O; Pakbaz, Z; Porter, J; Rofail, D; Swerdlow, P; Vichinsky, E | 1 |
8 review(s) available for deferasirox and HbS Disease
| Article | Year |
|---|---|
Deferasirox versus deferoxamine in managing iron overload in patients with Sickle Cell Anaemia: a systematic review and meta-analysis.
Topics: Anemia, Sickle Cell; Benzoates; Deferasirox; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Triazoles | 2022 |
Efficacy and safety of iron chelators in thalassemia and sickle cell disease: a multiple treatment comparison network meta-analysis and trial sequential analysis.
Topics: Anemia, Sickle Cell; Benzoates; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Humans; Iron Chelating Agents; Iron Overload; Network Meta-Analysis; Pyridones; Randomized Controlled Trials as Topic; Silymarin; Thalassemia; Triazoles | 2018 |
Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Benzoates; beta-Thalassemia; Chelation Therapy; Child; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Patient Compliance; Pyridones; Quality of Life; Randomized Controlled Trials as Topic; Triazoles | 2018 |
Deferasirox for managing transfusional iron overload in people with sickle cell disease.
Topics: Anemia, Sickle Cell; Benzoates; Chelation Therapy; Deferasirox; Deferoxamine; Erythrocyte Transfusion; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Randomized Controlled Trials as Topic; Triazoles | 2010 |
Iron-chelating therapy for transfusional iron overload.
Topics: Adolescent; Anemia, Sickle Cell; Benzoates; Chelation Therapy; Deferasirox; Deferoxamine; Erythrocyte Transfusion; Humans; Iron; Iron Chelating Agents; Iron Overload; Male; Practice Guidelines as Topic; Triazoles | 2011 |
[Iron chelating therapy in adults: How and when ?].
Topics: Anemia, Sickle Cell; Benzoates; beta-Thalassemia; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Myelodysplastic Syndromes; Myocardium; Pyridones; Siderophores; Triazoles | 2013 |
Investigational agents for sickle cell disease.
Topics: Acetamides; Anemia, Sickle Cell; Animals; Antihypertensive Agents; Antisickling Agents; Benzaldehydes; Benzoates; Carnitine; Cell Adhesion; Deferasirox; Endothelium, Vascular; Etilefrine; Female; Genetic Therapy; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Hypertension, Pulmonary; Iron Chelating Agents; Male; Membrane Glycoproteins; Potassium Channels, Calcium-Activated; Priapism; Recombinant Fusion Proteins; Triazoles; Trityl Compounds; Vasoconstrictor Agents | 2006 |
Chelation therapy for iron overload.
Topics: Anemia; Anemia, Sickle Cell; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Hemochromatosis; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Pyridones; Triazoles | 2007 |
10 trial(s) available for deferasirox and HbS Disease
| Article | Year |
|---|---|
Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial.
Topics: Administration, Oral; Adolescent; Agranulocytosis; Albania; Anemia, Sickle Cell; beta-Thalassemia; Cardiac Imaging Techniques; Child; Child, Preschool; Cyprus; Deferasirox; Deferiprone; Egypt; Erythrocyte Transfusion; Female; Ferritins; Greece; Hemoglobinopathies; Humans; Infant; Iron Chelating Agents; Iron Overload; Italy; Magnetic Resonance Imaging; Male; Patient Compliance; Treatment Outcome; Tunisia; United Kingdom; Urologic Diseases | 2020 |
Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial.
Topics: Acute Chest Syndrome; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Benzoates; Chelation Therapy; Child; Child, Preschool; Cohort Studies; Deferasirox; Female; Humans; Hydroxyurea; Incidence; Iron Chelating Agents; Iron Overload; Male; Pain Measurement; Phlebotomy; Secondary Prevention; Stroke; Transfusion Reaction; Triazoles; Young Adult | 2013 |
Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea.
Topics: Acute Kidney Injury; Adolescent; Adult; Anemia, Sickle Cell; Benzoates; Cellulitis; Chelation Therapy; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Deferasirox; Deferoxamine; Drug Therapy, Combination; Female; Ferritins; Humans; Hydroxyurea; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Prospective Studies; Transfusion Reaction; Triazoles; Young Adult | 2013 |
Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Benzoates; Biological Assay; Child; Child, Preschool; Deferasirox; Deferoxamine; Female; Humans; Hydroxyurea; Iron; Iron Chelating Agents; Iron Overload; Liver; Magnetic Resonance Imaging; Male; Stroke; Transfusion Reaction; Triazoles; Ultrasonography, Doppler, Transcranial | 2015 |
Deferasirox effectively decreases iron burden in patients with double heterozygous HbS/β-thalassemia.
Topics: Adult; Anemia, Sickle Cell; Benzoates; beta-Thalassemia; Deferasirox; Down-Regulation; Female; Hemoglobin, Sickle; Heterozygote; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Male; Middle Aged; Radiography; Triazoles | 2011 |
Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease.
Topics: Adolescent; Adult; Aged; Anemia, Sickle Cell; Benzoates; Child; Child, Preschool; Deferasirox; Drug Administration Schedule; Female; Gastrointestinal Diseases; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Transfusion Reaction; Treatment Outcome; Triazoles; Young Adult | 2011 |
Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention.
Topics: Adolescent; Anemia, Sickle Cell; Benzoates; Chelation Therapy; Child; Deferasirox; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Male; Secondary Prevention; Stroke; Transfusion Reaction; Triazoles; Young Adult | 2012 |
Two-year analysis of efficacy and safety of deferasirox treatment for transfusional iron overload in sickle cell anemia patients.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Benzoates; Deferasirox; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Prospective Studies; Triazoles; Young Adult | 2012 |
A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.
Topics: Administration, Oral; Adolescent; Adult; Alanine Transaminase; Anemia, Sickle Cell; Benzoates; Blood Transfusion; Chelation Therapy; Child; Child, Preschool; Deferasirox; Deferoxamine; Drug Administration Schedule; Female; Headache; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Male; Respiratory Tract Infections; Treatment Outcome; Triazoles | 2007 |
Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trial.
Topics: Absenteeism; Adolescent; Adult; Anemia, Sickle Cell; Benzoates; Chelation Therapy; Child; Child, Preschool; Deferasirox; Deferoxamine; Female; Hemosiderosis; Humans; Iron; Iron Chelating Agents; Male; Middle Aged; Patient Satisfaction; Surveys and Questionnaires; Transfusion Reaction; Treatment Outcome; Triazoles | 2008 |
19 other study(ies) available for deferasirox and HbS Disease
| Article | Year |
|---|---|
Iron Chelators, Such as Deferasirox, When Combined With Hydroxyurea, Provide an Additional Benefit of Iron Chelation in Patients Receiving Chronic Transfusion Therapy.
Topics: Alanine Transaminase; Anemia, Sickle Cell; Aspartate Aminotransferases; Chelation Therapy; Creatinine; Deferasirox; Ferritins; Humans; Hydroxyurea; Iron; Iron Chelating Agents; Iron Overload; Lactate Dehydrogenases | 2022 |
Hyperammonemia and acute liver failure associated with deferasirox in two adolescents with sickle cell disease.
Topics: Adolescent; Anemia, Sickle Cell; Benzoates; Deferasirox; Humans; Hyperammonemia; Iron Chelating Agents; Liver Failure, Acute | 2023 |
The challenges of handling deferasirox in sickle cell disease patients older than 40 years.
Topics: Adult; Aged; Anemia, Sickle Cell; Deferasirox; Female; Humans; Iron Chelating Agents; Male; Middle Aged; Prospective Studies | 2019 |
Adherence to Iron Chelation Therapy with Deferasirox Formulations among Patients with Sickle Cell Disease and β-thalassemia.
Topics: Anemia, Sickle Cell; beta-Thalassemia; Chelation Therapy; Deferasirox; Humans; Iron; Iron Chelating Agents; Retrospective Studies | 2021 |
A 3-year study of deferasirox therapy in sickle cell disease patients in Basra, Southern Iraq.
Topics: Abdominal Pain; Alanine Transaminase; Anemia, Sickle Cell; Benzoates; Blood Transfusion; Creatinine; Deferasirox; Female; Ferritins; Humans; Iraq; Iron Chelating Agents; Iron Overload; Male; Treatment Outcome; Triazoles | 2018 |
Deferasirox in children with transfusion-dependent thalassemia or sickle cell anemia: A large cohort real-life experience from Turkey (REACH-THEM).
Topics: Adolescent; Anemia, Sickle Cell; Biomarkers; Blood Transfusion; Child; Child, Preschool; Cohort Studies; Deferasirox; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Male; Thalassemia; Treatment Outcome; Turkey | 2019 |
Reversible retinopathy associated with oral deferasirox therapy.
Topics: Administration, Oral; Adolescent; Anemia, Sickle Cell; Benzoates; Deferasirox; Female; Humans; Iron Chelating Agents; Retinal Diseases; Triazoles; Visual Acuity | 2013 |
Deferasirox for iron chelation in multitransfused children with sickle cell disease; long-term experience in the East London clinical haemoglobinopathy network.
Topics: Adolescent; Alanine Transaminase; Anemia, Sickle Cell; Benzoates; Child; Child, Preschool; Deferasirox; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Kidney Function Tests; Liver; London; Male; Medication Adherence; Retrospective Studies; Time Factors; Transfusion Reaction; Treatment Outcome; Triazoles | 2015 |
Acute Liver Failure During Deferasirox Chelation: A Toxicity Worth Considering.
Topics: Anemia, Sickle Cell; Benzoates; Bilirubin; Blood Transfusion; Child; Deferasirox; Ferritins; Humans; Iron Chelating Agents; Liver Failure, Acute; Male; Transaminases; Triazoles | 2017 |
Hypocalcemia in a dialysis patient treated with deferasirox for iron overload.
Topics: Adult; Anemia, Sickle Cell; Benzoates; Deferasirox; Erythropoietin; Female; Humans; Hypertension; Hypocalcemia; Iron Chelating Agents; Iron Overload; Kidney Failure, Chronic; Peritoneal Dialysis; Transfusion Reaction; Triazoles | 2008 |
Adherence to deferasirox in children and adolescents with sickle cell disease during 1-year of therapy.
Topics: Adolescent; Anemia, Sickle Cell; Benzoates; Blood Transfusion; Child; Deferasirox; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Male; Parents; Patient Compliance; Surveys and Questionnaires; Triazoles | 2009 |
Deferasirox (Exjade) for the treatment of iron overload.
Topics: Anemia; Anemia, Sickle Cell; Benzoates; Deferasirox; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Rare Diseases; Thalassemia; Triazoles | 2009 |
Iron chelation therapy for patients with sickle cell disease and iron overload.
Topics: Administration, Oral; Anemia, Sickle Cell; Benzoates; Chelation Therapy; Child; Deferasirox; Deferiprone; Deferoxamine; Drug Monitoring; Erythrocyte Transfusion; Humans; Infusion Pumps; Infusions, Subcutaneous; Iron Chelating Agents; Iron Overload; Male; Pain; Patient Compliance; Pyridones; Sensation Disorders; Social Isolation; Triazoles; Young Adult; Zinc | 2010 |
Persistence and compliance of deferoxamine versus deferasirox in Medicaid patients with sickle-cell disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Sickle Cell; Benzoates; Child; Child, Preschool; Cohort Studies; Deferasirox; Deferoxamine; Female; Florida; Hospitalization; Humans; Iron Chelating Agents; Kaplan-Meier Estimate; Male; Medicaid; Medication Adherence; Middle Aged; Missouri; New Jersey; Retrospective Studies; Triazoles; United States; Young Adult | 2012 |
Oxidative stress and antioxidant capacity in sickle cell anaemia patients receiving different treatments and medications for different periods of time.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antioxidants; Benzoates; Biomarkers; Blood Transfusion; Child; Deferasirox; Female; Humans; Iron Chelating Agents; Lipid Peroxidation; Longitudinal Studies; Male; Middle Aged; Oxidative Stress; Thiobarbituric Acid Reactive Substances; Triazoles; Young Adult | 2012 |
Challenges of adherence and persistence with iron chelation therapy.
Topics: Administration, Oral; Adolescent; Anemia, Sickle Cell; Benzoates; beta-Thalassemia; Child; Deferasirox; Deferiprone; Deferoxamine; Dosage Forms; Humans; Infusions, Intravenous; Iron Chelating Agents; Iron Overload; Patient Care Team; Patient Compliance; Pyridones; Time Factors; Triazoles | 2011 |
Long-term persistency and costs associated with the use of iron chelation therapies in the treatment of Sickle cell disease within Medicaid programs.
Topics: Adolescent; Adult; Age Factors; Anemia, Sickle Cell; Benzoates; Blood Transfusion; Child; Deferasirox; Deferoxamine; Drug Utilization; Female; Health Expenditures; Humans; Insurance Claim Review; Iron Chelating Agents; Kaplan-Meier Estimate; Male; Medicaid; Medication Adherence; Patient Preference; Proportional Hazards Models; Racial Groups; Retrospective Studies; Sex Factors; Triazoles; United States | 2013 |
Safety and efficacy of 4 years of deferasirox treatment for sickle cell disease patients.
Topics: Adult; Anemia, Sickle Cell; Benzoates; Deferasirox; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Liver; Male; Middle Aged; Pilot Projects; Triazoles | 2013 |
Strides made in red blood cell disorders, but substantial barriers to care remain.
Topics: Anemia, Sickle Cell; Antisickling Agents; Benzoates; Brain Diseases; Chelation Therapy; Deferasirox; Hematologic Diseases; Hematology; Humans; Hydroxyurea; Iron Chelating Agents; Triazoles | 2008 |